Advertisement - Members don't see this ad
Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain
/PRNewswire/ -- Medtronic plc (NYSE: MDT), a global healthcare technology leader, today announced its intent to acquire SPR Therapeutics, Inc. (SPR), a...
"The PNS segment continues to grow, driven by increasing clinical evidence, expanding reimbursement, and demand for non-opioid, less-invasive pain therapies. To date, the largest retrospective review of real-world PNS data, which includes more than 6,100 patients, was conducted using the SPRINT PNS System and showed over 71 percent of study participants demonstrated significant pain relief and/or improvement in quality of life following 60-day percutaneous PNS treatment."